Departament d'Enginyeria Química, Universitat Autònoma de Barcelona, Campus Bellaterra, Cerdanyola del Vallès 08193, Barcelona, Spain.
J Biotechnol. 2013 Jul 20;166(4):152-65. doi: 10.1016/j.jbiotec.2013.05.001. Epub 2013 May 17.
Virus-like particles (VLPs) offer great promise as candidates for new vaccine strategies. Large-scale approaches for the manufacturing of HIV-1 Gag VLPs have mainly focused on the use of the baculovirus expression system. In this work, the development and optimization of an HIV-1 Gag VLP production protocol by transient gene expression in mammalian cell suspension cultures is reported. To facilitate process optimization, a Gag-GFP fusion construct enabling the generation of fluorescent VLPs was used. The great majority of Gag-GFP present in cell culture supernatants was shown to be correctly assembled into virus-like particles of the expected size and morphology consistent with immature HIV-1 particles. Medium optimization was performed using design of experiments (DoE). Culture medium supplementation with non-animal derived components including recombinant proteins and lipids of synthetic or non-animal-derived origin resulted in improved HEK 293 cell growth and VLP production. The maximum cell density attained using the optimized Freestyle culture medium was 5.4×10(6)cells/mL in batch mode, almost double of that observed using the unsupplemented medium (2.9×10(6)cells/mL). Best production performance was attained when cells were transfected at mid-log phase (2-3×10(6)cells/mL) with medium exchange at the time of transfection using standard amounts of plasmid DNA and polyethylenimine. By using an optimized production protocol, VLP titers were increased 2.4-fold obtaining 2.8μg of Gag-GFP/mL or 2.7×10(9)VLPs/mL according to ELISA and nanoparticle tracking quantification analyses, respectively.
病毒样颗粒 (VLPs) 作为新型疫苗策略的候选物具有很大的潜力。用于制造 HIV-1 Gag VLPs 的大规模方法主要集中在使用杆状病毒表达系统上。在这项工作中,报告了通过哺乳动物悬浮细胞培养中的瞬时基因表达来开发和优化 HIV-1 Gag VLP 生产方案。为了便于进行工艺优化,使用了一种能够产生荧光 VLP 的 Gag-GFP 融合构建体。在细胞培养上清液中存在的大量 Gag-GFP 被证明已正确组装成预期大小和形态的病毒样颗粒,与不成熟的 HIV-1 颗粒一致。使用实验设计 (DoE) 进行了培养基优化。用非动物衍生成分(包括重组蛋白和合成或非动物衍生来源的脂质)补充培养基可提高 HEK 293 细胞的生长和 VLP 的生产。使用优化的 Freestyle 培养基在批次模式下达到的最大细胞密度为 5.4×10(6)个细胞/mL,几乎是未补充培养基的两倍(2.9×10(6)个细胞/mL)。当细胞在对数中期(2-3×10(6)个细胞/mL)时进行转染,并在转染时使用标准量的质粒 DNA 和聚乙烯亚胺进行培养基交换时,可获得最佳的生产性能。通过使用优化的生产方案,VLP 滴度提高了 2.4 倍,根据 ELISA 和纳米颗粒跟踪定量分析,分别获得 2.8μg Gag-GFP/mL 或 2.7×10(9)VLPs/mL。